###begin article-title 0
###xml 27 30 27 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 68 73 <span type="species:ncbi:10090">mouse</span>
Identification of a direct Dlx homeodomain target in the developing mouse forebrain and retina by optimization of chromatin immunoprecipitation
###end article-title 0
###begin p 1
###xml 95 119 95 119 <email xmlns:xlink="http://www.w3.org/1999/xlink">eisensta@cc.umanitoba.ca</email>
To whom correspondence should be addressed. Tel: +1 204 787 1169; Fax: +1 204 787 2190; Email: eisensta@cc.umanitoba.ca
###end p 1
###begin p 2
###xml 144 147 144 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 240 243 240 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 245 248 245 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 361 364 361 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 370 373 370 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 541 548 541 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 788 791 788 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 793 796 793 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 879 886 879 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 1019 1027 1019 1027 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1172 1175 1172 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1221 1228 1221 1228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 1291 1294 1291 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1327 1334 1327 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 266 270 <span type="species:ncbi:10090">mice</span>
Understanding homeobox gene specificity and function has been hampered by the lack of proven direct transcriptional targets during development. Dlx genes are expressed in the developing forebrain, retina, craniofacial structures and limbs. Dlx1/Dlx2 double knockout mice die at birth with multiple defects including abnormal forebrain development and decreased Dlx5 and Dlx6 expression. We have successfully applied chromatin immunoprecipitation (ChIP) to identify a direct transcriptional target of DLX homeoproteins from embryonic tissues in vivo. We optimized cross-linking conditions to enrich for protein-DNA complexes, then using specific high affinity DLX antibodies captured immunoenriched DLX genomic DNA transcriptional targets. DLX homeobox proteins bind differentially to the Dlx5/Dlx6 intergenic enhancer in newborn retina (DLX2) and embryonic striatum (DLX1, DLX2) in situ. Reporter gene assays demonstrated the functional significance of the binding of DLX proteins to this regulatory element, confirmed in vitro by electrophoretic mobility shift assays, using tissue extracts or recombinant DLX proteins. ChIP provides the best approach to identify direct Dlx homeoprotein targets from developing tissues in situ. The use of this technology will advance our understanding of Dlx gene function in the vertebrate in vivo and can be applied to examine targets of other homeobox genes and other classes of transcription factors.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c1">1</xref>
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c2">2</xref>
###xml 254 261 254 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
Homeobox genes are transcription factors of fundamental importance during the development of evolutionarily diverse species. They have been implicated in many congenital malformations and developmental cancers (1,2). Insights into homeobox gene function in vivo have been gained through the mutagenesis, inactivation or ectopic expression of these genes in different animal models. However, there is little known about the identity of direct homeobox gene targets. It is critical to identify these 'downstream' genes to understand the genetic program used by homeobox genes to determine regional identity, patterning and cell-fate specification during vertebrate development.
###end p 4
###begin p 5
###xml 19 22 19 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 108 109 108 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c3">3</xref>
###xml 110 111 110 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c6">6</xref>
###xml 118 121 118 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f3">3</xref>
###xml 225 226 225 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c7">7</xref>
###xml 247 250 247 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 256 259 256 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c8">8</xref>
###xml 489 492 489 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 648 649 648 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c9">9</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c10">10</xref>
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
###xml 229 233 <span type="species:ncbi:10090">Mice</span>
###xml 630 634 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
Of six known mouse Dlx genes, four (Dlx1, 2, 5 and 6) are expressed in the developing forebrain and retina (3-6). The Dlx genes are arranged in bigenic clusters where each pair is linked to a different Hox cluster (Fig. 3a) (7). Mice lacking both Dlx1 and Dlx2 exhibit a time-dependent block in striatal neuronogenesis (8). Neurons born after embryonic day 12.5 (E12.5) do not fully differentiate and are blocked in their migration to the neocortex, olfactory bulb and hippocampus. In the Dlx1/2 mutants, a lateral tangential migration that appears to be the source for most neocortical GABAergic interneurons present in neonatal mice, is blocked (9,10). As well, we have demonstrated abnormal retinal development in these doubly null mice (de Melo,J., Du,G., Fonseca,M., Turk,W.J., Rubenstein,J.L.R. and Eisenstat,D.D., submitted).
###end p 5
###begin p 6
###xml 31 34 31 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c3">3</xref>
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c3">3</xref>
###xml 369 370 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c6">6</xref>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c8">8</xref>
###xml 402 405 402 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 558 561 558 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 567 570 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 573 574 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c11">11</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c12">12</xref>
The redundant functions of the Dlx genes may be explained by their nearly identical homeodomains, whereas their unique functions may be due to the divergence of their amino acid sequences in other domains (3). In addition, while Dlx1, 2, 5 and 6 are localized to the same anatomical regions, they are expressed at different but overlapping stages of differentiation (3,4,6,8), suggesting that distinct Dlx genes are required at different stages of development. This temporal and spatial overlap could be the basis for the observed genetic redundancy between Dlx1 and Dlx2 (4,11,12).
###end p 6
###begin p 7
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 40 44 40 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Dlx</italic>
###xml 71 74 71 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 167 170 167 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 243 246 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c14">14</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c15">15</xref>
###xml 274 277 274 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/Dlx</italic>
###xml 389 392 389 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 398 401 398 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 421 424 421 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 426 429 426 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 455 456 455 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c8">8</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c16">16</xref>
###xml 690 697 690 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 824 827 824 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 832 835 832 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 846 849 846 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 858 861 858 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 874 881 874 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 65 70 <span type="species:ncbi:10090">mouse</span>
###xml 495 500 <span type="species:ncbi:10090">mouse</span>
A conserved enhancer located in the Dlx5/Dlx6 intergenic region (mouse Dlx5/6 intergenic enhancer; MI56) is an important site of cross-regulatory interactions between Dlx genes (13) and shows sequence similarity to an intergenic region of the Dlx3-7 cluster (14,15). In the Dlx1/Dlx2 knockout, activity of a reporter transgene regulated by MI56 is markedly reduced, analogous to decreased Dlx5 and Dlx6 expression in the Dlx1/Dlx2 double mutant striatum (8,13). Expression from MI56 marks adult mouse cortical GABAergic interneurons (16). However, these studies have not addressed whether the observed transcriptional events are due to the direct interaction of DLX homeoproteins with MI56 in vivo or via an indirect mechanism, such as regulation of other transcription factors. Here, we demonstrate for the first time that Dlx1 or Dlx2 regulate Dlx5 and/or Dlx6 expression in vivo by direct transcriptional regulation of MI56 by adapting chromatin immunoprecipitation (ChIP) to the developing vertebrate forebrain and retina.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Animals
###end title 9
###begin p 10
###xml 260 263 260 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 265 268 265 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 290 294 290 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 321 323 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 19 23 <span type="species:ncbi:10090">mice</span>
###xml 315 319 <span type="species:ncbi:10090">mice</span>
Timed pregnant CD1 mice were sacrificed by cervical dislocation following protocols approved by the University of Manitoba under the auspices of the Canadian Council on Animal Care. The presence of a vaginal plug after mating denoted embryonic day 0.5 (E0.5). Dlx5/Dlx6 intergenic enhancer-lacZ transgenic reporter mice (13) were obtained from M. Ekker (University of Ottawa, Canada), maintained in a CD1 background.
###end p 10
###begin title 11
Chromatin immunoprecipitation
###end title 11
###begin p 12
###xml 276 277 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 633 634 633 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 635 636 635 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c9">9</xref>
###xml 658 659 658 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c17">17</xref>
###xml 1323 1324 1317 1318 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 119 123 <span type="species:ncbi:10090">mice</span>
The medial and lateral ganglionic eminences (GE) and hindbrain tissue were dissected from embryonic day 13.5 (E13) CD1 mice and mechanically triturated to obtain single cells. Retinal tissue at birth (postnatal day 0; P0) was obtained by first removing the lens. Then 1-2 x 107 cells were cross-linked with 1% paraformaldehyde (PFA) for 2 h at room temperature (RT) in the presence of protease inhibitors. Cross-linked cells were resuspended in SDS lysis buffer (1% SDS, 50 mM Tris-HCl pH 8.1, 10 mM EDTA), then sonicated. Protein A-Sepharose beads (Pharmacia Biotech) were added to the supernatant to pre-clear the chromatin. DLX1 (4,9) or DLX2 antibodies (4,17) were repurified to obtain fractions with high-affinity binding, then added to the chromatin solution and incubated overnight at 4degreesC. Then Protein A and Protein G-Sepharose (Sigma) were added and incubated for 3 h. Pelleted beads were then sequentially washed with Low Salt Wash Buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, 150 mM NaCl), High Salt Wash Buffer (with 500 mM NaCl), LiCl Buffer (0.25 M LiCl, 1% deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.1, 1% NP-40) and TE buffer (10 mM Tris-Cl, 1 mM EDTA, pH 8.0). The enriched homeoprotein DNA complex was eluted twice using freshly prepared Elution Buffer (1% SDS, 0.1 M NaHCO3) and centrifuged. Then 4 M NaCl was added to the supernatant to reverse cross-linking, and incubated at 65degreesC for 4 h. Finally, proteinase K was added for 1 h at 45degreesC. Phenol/chloroform was used to extract residual proteins from the DNA.
###end p 12
###begin title 13
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
cis-Diamminedichloroplatinum (cis-DDP) crosslinking
###end title 13
###begin p 14
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 265 266 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 268 269 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 690 692 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c18">18</xref>
###xml 693 695 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c21">21</xref>
1-2 x 107 cells isolated from E13.5 GE were suspended with cold Hanks' buffer containing 1 mM PMSF, centrifuged and washed, then resuspended in 1 mM cis-DDP solution (Sigma) and incubated at 37degreesC for 2 h. Then the cells were lysed using lysis buffer (200 mM K3PO4 pH 7.5, 5 M urea, 2 M guanidine-HCl, 2 M NaCl) with 1 mM PMSF and mixed with hydroxylapatite (HAP) resin (Bio-Rad) pre-equilibrated with lysis buffer for 1 h incubation at 4degreesC. Proteins cross-linked to DNA were released from the HAP-bound DNA by a 2 h incubation at 4degreesC with reverse lysis buffer (1 M thiourea is substituted for 5 M urea), dialyzed, lyophilized, then analyzed by SDS-PAGE and immunoblotted (18-21).
###end p 14
###begin title 15
Polymerase chain reaction (PCR)
###end title 15
###begin p 16
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 409 414 <span type="species:ncbi:10090">mouse</span>
Oligonucleotide primers were designed according to two regions of the MI56 sequence (GenBank, AY168010), I56i and I56ii (13). For I56i, the sense primer was 5'-GACATTGGGGACAATTTA-3' and the antisense primer was 5'-AATTTGTGTATGAATAAC-3'. For I56ii, the sense primer was 5'-GTTTGCACACCCCAGCACCTCT-3' and the antisense primer was 5'-CAGCCATTATTTAGACCCTA-3'. PCR was carried out with genomic DNA derived from E13 mouse embryo used as a positive control. PCR products were separated by gel electrophoresis, purified then ligated into the pCR2.1 TOPO vector using a TOPO TA cloning kit (Invitrogen). Recombinant plasmid DNA was extracted using a Plasmid MiniPrep Kit (Qiagen Inc.) and M13 reverse universal primer was used for confirmation of sequence.
###end p 16
###begin title 17
Electrophoretic mobility shift assays
###end title 17
###begin p 18
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 265 267 261 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 412 414 408 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 442 443 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 620 626 <span type="species:ncbi:9986">rabbit</span>
###xml 650 655 <span type="species:ncbi:9606">human</span>
The Dlx5/6 intergenic region I56i, nucleotides 8688-8917 (GenBank, AY168010), was excised from pCR2.1-TOPO vector (Invitrogen) with EcoRI, then the 5' overhang was filled in with the large fragment of DNA polymerase I (Klenow) in the presence of radiolabeled [alpha32P]dATP. Purified recombinant protein or nuclear extracts from the E13 striatum were incubated with 1x binding buffer, poly(dI-dC), 1 mM PMSF and 32P-labeled DNA probes (2 x 104 c.p.m.). For 'cold' competition assays, double-stranded unlabeled fragments were added. For 'supershift' assays, the specific polyclonal DLX1 and DLX2 antibodies were added. A rabbit polyclonal antibody to human Secretory Component (Dako) was used as an 'irrelevant' antibody. Reactions were incubated for 30 min at RT. The DNA-protein complexes were resolved on a 4% non-denaturing polyacrylamide (37.5:1 acrylamide/bis-acrylamide) gel in 0.5x Tris-borate-EDTA solution. Gels were exposed to film and autoradiography was performed overnight at -70degreesC.
###end p 18
###begin p 19
###xml 76 77 76 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f3">3</xref>
###xml 318 324 318 324 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TAATTA</bold>
###xml 358 364 358 364 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TAATTA</bold>
###xml 408 412 408 412 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ATTA</bold>
###xml 450 454 450 454 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TAAT</bold>
###xml 494 498 494 498 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TAAT</bold>
###xml 548 552 548 552 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ATTA</bold>
###xml 596 602 596 602 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TAATTA</bold>
###xml 634 640 634 640 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TAATTA</bold>
Sequences of four of 10 putative TAAT/ATTA homeodomain binding motifs (Fig. 3b) from the I56i region were used to generate individual synthetic oligonucleotides (16-20 bp). Double-stranded oligonucleotides were subjected to further electrophoretic mobility shift assay (EMSA) analysis. Motif 6: sense primer: 5'-CAAAGATAATTACCTG-3', antisense primer: 5'-CAGGTAATTATCTTTG-3'; Motif 7: sense primer: 5'-CCCGCTGATTACAGCGT-3', antisense primer: 5'-ACGCTGTAATCAGCGGG-3'; Motif 8: sense primer: 5'-AGTAATTTTTCATGGAGC-3', antisense primer: 5'-GCTACATGAAAAATTACT-3'; Motif 9: sense primer: 5'-AAATGCAGCCATAATTAGAG-3', antisense primer: 5'-CTCTAATTATGGCTGCATTT-3'. Putative homeodomain protein recognition sites as characterized by a TAAT/ATTA core sequence are in bold.
###end p 19
###begin title 20
Constructs for reporter gene assays
###end title 20
###begin p 21
###xml 39 42 39 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 155 158 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 177 180 177 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
###xml 89 92 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Effector plasmids expressing the mouse Dlx1 and Dlx2 genes separately under control of a CMV promoter were constructed by inserting a PCR-amplified 790 bp Dlx1 cDNA and 1020 bp Dlx2 cDNA (gifts from J. Rubenstein, UCSF) into the pcDNA3 vector (Invitrogen). Reporter plasmids were constructed by inserting a 236 bp I56i intergenic enhancer fragment from position 8688-8917 (GenBank, AY168010) into the pGL3-promoter vector (Promega). Site-directed mutagenesis of putative DLX-binding sites was performed using the Quick Change kit (Stratagene). Three pGL3 promoter plasmids were generated containing deleted MI56i elements (ATAATTA). The first plasmid (Delta1) contained a deletion at nucleotides 8853-8860, the second plasmid (Delta2) contained a deletion at 8797-8804 and the third plasmid (Delta3) contained a deletion at both of these positions. Mutations were verified by DNA sequencing.
###end p 21
###begin title 22
Reporter gene assays
###end title 22
###begin p 23
###xml 369 370 359 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 437 438 427 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 448 449 438 439 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 64 70 <span type="species:ncbi:10090">murine</span>
###xml 284 290 <span type="species:ncbi:9913">bovine</span>
###xml 303 307 <span type="species:ncbi:9913">calf</span>
Transient co-transfection experiments were performed in the P19 murine embryonic carcinoma (EC) cell line (a gift from M. McBurney, University of Ottawa, Canada). P19 cells were grown and maintained in alpha Dulbecco's Modified Eagle's medium (alphaDMEM) supplemented with 7.5% fetal bovine serum, 2.5% calf serum and 1% penicillin-streptomycin at 37degreesC with 5% CO2. Cells were seeded 24 h before transfection at a density of 1 x 107 per 36 mm2 dish. Cells were transiently transfected using Lipofectamine 2000 reagent (Invitrogen). All transfections contained pRSV-beta-gal (Promega) as a control for transfection efficiency. Luciferase activity was measured using the Luciferase Reporter Assay System (Promega) and a standard luminometer.
###end p 23
###begin title 24
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
Immunoblot, in situ hybridization, immunostaining, beta-galactosidase staining
###end title 24
###begin p 25
###xml 12 19 12 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 165 166 165 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c6">6</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c17">17</xref>
###xml 431 433 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 434 436 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c16">16</xref>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 210 216 <span type="species:ncbi:9986">rabbit</span>
###xml 240 246 <span type="species:ncbi:9986">rabbit</span>
###xml 296 302 <span type="species:ncbi:9986">rabbit</span>
###xml 356 362 <span type="species:ncbi:9986">rabbit</span>
Immunoblot, in situ hybridization and immunostaining were performed on fixed, cryopreserved retinal tissues at P0 and in adult mice following established protocols (4,6,17). Primary antibodies were: alphaDLX1, rabbit polyclonal; alphaDLX2, rabbit polyclonal; anti-beta-gal (ICN Pharmaceuticals), rabbit polyclonal; alphaHDAC1 (Affinity Bioreagents, Inc.), rabbit polyclonal. beta-galactosidase staining was performed as described (13,16).
###end p 25
###begin title 26
RESULTS
###end title 26
###begin title 27
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
Dlx gene expression in embryonic forebrain and retina tissues
###end title 27
###begin p 28
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c3">3</xref>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c17">17</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 177 178 177 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c6">6</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
Both DLX1 and DLX2 are highly expressed in the anlagen of the embryonic striatum, the medial and lateral GE (Fig. 1a, A and B) (3,4,17), retinal neuroepithelium (Fig. 1a, C) (4,6) and the ventral thalamus (data not shown). Peak levels of expression occur in forebrain tissues before E14.5 (4).
###end p 28
###begin title 29
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 41 44 41 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
Dlx genes are co-expressed with the Dlx5/Dlx6 intergenic enhancer in the retina
###end title 29
###begin p 30
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 9 12 9 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 59 62 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 146 149 146 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 155 158 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c6">6</xref>
###xml 452 459 452 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 495 498 495 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 510 513 510 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 558 561 558 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 605 608 605 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 613 616 613 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 624 625 624 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c6">6</xref>
###xml 672 675 672 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 755 756 755 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 797 800 797 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 860 861 860 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 938 939 938 939 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 990 997 990 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
Dlx1 and Dlx2 expression in the retina occurs after E12.5. Dlx5 is not expressed at this stage (4). We have completed a comprehensive analysis of Dlx1 and Dlx2 expression during retinal development. DLX1 expression is similar to DLX2 but is markedly reduced after birth (P0). In the adult, DLX2 is localized to retinal ganglion cells (RGC), amacrine cells, horizontal cells and a subset of bipolar cells, but not to photoreceptors (6). Digoxigenin RNA in situ hybridization studies demonstrated Dlx1, Dlx2 and Dlx5 retinal expression at P0 and in the adult. Dlx2 is expressed at higher levels than either Dlx1 or Dlx5 (Fig. 1b) consistent with its protein expression (6). Dlx5 is first expressed after E16, primarily in the ganglion cell layer (GCL, Fig. 1b, C and F) and DLX2 protein (brown) and Dlx5 RNA (blue purple) are co-expressed in the GCL at P0 (Fig. 1c, A) and in the GCL and inner nuclear layer (INL) in the adult retina (Fig. 1c, B) using combined immunohistochemistry with RNA in situ hybridization.
###end p 30
###begin p 31
###xml 4 7 4 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 114 117 114 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 158 161 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 222 225 222 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 238 242 238 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 286 287 286 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c5">5</xref>
###xml 288 290 288 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 291 293 291 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c16">16</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c22">22</xref>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 392 396 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 474 475 474 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 510 514 510 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 558 561 558 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 738 741 738 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 832 839 832 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
The Dlx5/6 intergenic enhancer/lacZ mouse expresses lacZ in anatomic locations where Dlx5, and to a lesser extent Dlx6, are expressed (13). Although Dlx1 and Dlx2 expression is significantly reduced in late gestation, the Dlx5/6 enhancer lacZ transgene may be expressed into adulthood (5,13,16,22). In the retina, lacZ expression was faintly detected at P0 (data not shown) but in the adult, lacZ was expressed in the GCL, containing RGCs and displaced amacrine cells (Fig. 1c). Adult retinal cells expressing lacZ (X-gal) co-expressed a digoxigenin-labeled Dlx5 riboprobe (Fig. 1c, C) and a subset were immunoreactive for DLX2 (Fig. 1c, D). Hence, DLX2 and MI56 are co-expressed in the GCL of the adult retina. These results support the Dlx5/6 intergenic enhancer as a candidate DLX1 or DLX2 target region in the developing retina in vivo.
###end p 31
###begin title 32
###xml 55 60 <span type="species:ncbi:10090">mouse</span>
Optimization of protein-DNA cross-linking in embryonic mouse forebrain and retina
###end title 32
###begin p 33
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 384 385 384 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f1">1</xref>
###xml 497 498 485 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 831 832 819 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f2">2</xref>
###xml 432 436 <span type="species:ncbi:10090">mice</span>
We have optimized ChIP of embryonic striatum and retina, with respect to anatomic region, developmental stage, cell number, selection and concentration of a cross-linking reagent, and duration of cross-linking. We chose E13.5 GE and P0 retina due to the ease of dissection and the relative abundance of DLX1 and DLX2 expression at these time-points (Fig. 1a, A, B; Fig. 1b, A-C; Fig. 1c, A). An average litter of timed pregnant CD1 mice yielded 10-15 paired GE or retinas for approximately1-2 x 107 cells. We then cross-linked the tissues with PFA concentrations ranging from 1 to 4% with fixation times from 30 min to overnight. PFA cross-links protein to protein, protein to DNA and DNA to DNA depending on the substrate and binding conditions. 1% PFA was superior to 4% for cross-linking DLX proteins to nuclear DNA in GE (Fig. 2a).
###end p 33
###begin p 34
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f2">2</xref>
The duration of exposure to PFA was also critical for obtaining suitable yields of homeoprotein-DNA complexes. In GE, peak levels of DLX1 and DLX2 were obtained at 90 min, with levels rapidly falling off after 2 h and negligible amounts were present after an overnight fixation (Fig. 2b). Incubation time with the cross-linking reagent affects the quantity of protein-DNA complexes as well as the solubility of these complexes.
###end p 34
###begin title 35
Cisplatin also cross-links DLX proteins to nuclear DNA in embryonic striatum
###end title 35
###begin p 36
###xml 11 14 11 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c18">18</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c20">20</xref>
###xml 291 298 291 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c18">18</xref>
###xml 303 305 303 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c20">20</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c23">23</xref>
###xml 378 385 378 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f2">2</xref>
###xml 535 542 535 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f2">2</xref>
Cisplatin (cis-DDP) was tested as an alternative to PFA since it cross-links nuclear DNA at 4 A rather than 2 A and cross-links protein to DNA rather than to protein (18,20). Cisplatin preferentially cross-links nuclear matrix proteins, such as histone deacetylase-1 (HDAC1), to nuclear DNA in situ (18-20,23). Cisplatin cross-linked DLX1, DLX2 and HDAC1 to nuclear DNA from GE in situ (Fig. 2c) suggesting that DLX1 and DLX2 are nuclear matrix proteins. Cisplatin (1 mM) is sufficient to cross-link either DLX1 or DLX2 to nuclear DNA in situ. This cross-linking reagent was less efficient than 1% PFA for yields of DLX1 or DLX2, but relatively higher levels of HDAC1 were obtained. Since PFA produced a greater yield of DLX1 and DLX2 cross-linked products, we chose 1% PFA as the cross-linking reagent for subsequent ChIP experiments (Fig. 2a,b).
###end p 36
###begin title 37
###xml 25 28 25 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
DLX proteins bind to the Dlx5/Dlx6 intergenic enhancer in embryonic striatum
###end title 37
###begin p 38
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c24">24</xref>
###xml 320 323 320 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 329 332 329 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f3">3</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 745 746 745 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f4">4</xref>
###xml 887 888 887 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f4">4</xref>
###xml 967 970 967 970 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 983 984 983 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f4">4</xref>
###xml 750 755 <span type="species:ncbi:10090">Mouse</span>
Using this optimized ChIP procedure and specific polyclonal antibodies to DLX1 and DLX2 (4), DLX1 and DLX2 target genomic DNA sequences were isolated. Following sonication, the average fragment size, representing candidate regulatory sequences, was 300 bp (24). We selected the intergenic enhancer region (MI56) between Dlx5 and Dlx6 (Fig. 3a and b) (13). MI56 has two candidate homeodomain binding regions based upon groups of putative TAAT/ATTA DNA binding motifs: the I56i region (nucleotides 8641-9039) and I56ii (6543-6840) both have 10 motifs (13). We designed oligonucleotide primers to encompass both MI56 regions and performed PCR after ChIP of E13 GE fixed in 1% PFA for 2 h. Both DLX1 and DLX2 bound to I56i but not I56ii in GE (Fig. 4a). Mouse genomic DNA was used as a positive control for PCR. Negative controls included omission of the specific antibody from the IP (Fig. 4a, b and c) and use of embryonic hindbrain, a tissue that does not express any Dlx genes (Fig. 4c). Bands obtained from PCR were subcloned and sequence-verified.
###end p 38
###begin title 39
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 54 57 54 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
DLX homeobox proteins differentially bind to the Dlx5/Dlx6 intergenic enhancer in the newborn retina
###end title 39
###begin p 40
###xml 56 57 56 57 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f4">4</xref>
###xml 154 161 154 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 220 223 220 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 350 351 350 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f4">4</xref>
ChIP assays of retina tissue at P0 were performed (Fig. 4b). Similar to E13 GE, DLX homeoproteins bind only to the I56i region, not to I56ii in P0 retina in situ. However, unlike striatum, DLX2 but not DLX1 binds to the Dlx5/6 intergenic enhancer in retina at P0, probably reflecting the marked reduction in DLX1 protein in the neonatal retina (Fig. 4b).
###end p 40
###begin title 41
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
Embryonic striatal nuclear extracts bind to specific homeodomain-DNA binding motifs of the Dlx5/Dlx6 intergenic enhancer
###end title 41
###begin p 42
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 105 112 105 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 180 188 180 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 247 252 247 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c25">25</xref>
###xml 526 527 526 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f5">5</xref>
EMSA were used to provide in vitro evidence for the binding of DLX1 and/or DLX2 to MI56 isolated by ChIP in situ. We demonstrated specific DLX1- and DLX2-oligonucleotide complexes in vitro similar to DLX3-oligonucleotide complexes shown by Feledy et al. (25). Recombinant DLX1 and DLX2 bind to the I56i region and specific supershifted bands result on the addition of specific DLX1 or DLX2 antibodies. The addition of an irrelevant polyclonal primary antibody confirms the specific binding of homeoprotein-DNA complexes (Fig. 5a).
###end p 42
###begin p 43
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f3">3</xref>
###xml 231 236 231 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 256 264 256 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f5">5</xref>
###xml 423 424 423 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f5">5</xref>
###xml 526 534 526 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 573 578 573 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 758 761 758 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 763 766 763 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 795 803 795 803 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
We then developed EMSA for nuclear extracts enriched for DLX1 and DLX2 expression obtained from GE and retina tissues. Several of the 10 TAAT motifs located in the I56i DNA binding region (Fig. 3b) were previously shown by Zerucha et al. (13) to bind DLX2 in vitro; DLX1 binding to this region was not previously assessed. We sequentially deleted each region and determined that only the ninth (Fig. 5b, A) and sixth (Fig. 5b, B) homeodomain binding motifs were sufficient for binding both DLX1 and DLX2 in embryonic striatum in vitro corroborating the findings of Zerucha et al. (13). Supershift experiments confirm the specificity of each DLX protein-DNA complex. Hence, both recombinant DLX1 and DLX2 and striatal nuclear extracts bind to region 1 of the Dlx5/Dlx6 intergenic enhancer (I56i) in vitro.
###end p 43
###begin title 44
###xml 112 115 112 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 117 120 117 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
The DLX2 homeoprotein preferentially activates reporter gene activity when bound to its target sequences in the Dlx5/Dlx6 intergenic enhancer
###end title 44
###begin p 45
###xml 129 137 129 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c26">26</xref>
###xml 955 956 955 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f6">6</xref>
###xml 1014 1019 1014 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1041 1044 1041 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dlx</italic>
###xml 1046 1049 1046 1049 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dlx</italic>
###xml 1072 1074 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
###xml 1031 1040 <span type="species:ncbi:7955">zebrafish</span>
Although the ChIP assay was used to isolate mouse I56i as a DLX1 and DLX2 DNA target and EMSA confirmed protein-DNA interactions in vitro, it is important to demonstrate the functional significance of DLX1 or DLX2 binding to this enhancer element. P19 embryonal carcinoma cells are pluripotential cells that can differentiate into neuronal cells under specific conditions, such as treatment with retinoic acid (26). DLX2, but not DLX1, co-transfection activated luciferase expression. Western blotting confirmed that recombinant DLX1 and DLX2 proteins are both made in the transfected P19 cells (data not shown). Site-directed mutagenesis of the sixth or ninth TAAT motifs was completed prior to co-transfection with DLX expression constructs. Mutation of the sixth motif significantly reduced reporter gene activity mediated by DLX2, whereas mutation of the ninth motif reduced luciferase activity to a lesser extent following DLX2 co-transfection (Fig. 6). These results are similar to those obtained by Zerucha et al. using the zebrafish dlx4/dlx6 intergenic enhancer (13). Unlike DLX2, reporter gene expression was not affected by DLX1 co-transfection studies with the intact I56i enhancer element or mutated I56i enhancers containing mutations of the sixth and ninth TAAT motifs. Co-transfection of both DLX1 and DLX2 did not demonstrate any additive or synergistic effects compared with co-transfection of DLX2 alone (data not shown).
###end p 45
###begin title 46
DISCUSSION
###end title 46
###begin p 47
###xml 149 152 149 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 154 157 154 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 202 209 202 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 290 293 290 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 299 302 299 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 357 360 357 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 362 365 362 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 390 391 390 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c8">8</xref>
###xml 563 566 563 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 383 388 <span type="species:ncbi:10090">mouse</span>
###xml 508 513 <span type="species:ncbi:10090">mouse</span>
We have optimized the ChIP assay, using our specific DLX1 and DLX2 antibodies, to demonstrate for the first time that both DLX1 and DLX2 bind to the Dlx5/Dlx6 intergenic enhancer in embryonic forebrain in vivo. Our results provide a direct mechanism to explain the marked reduction in both Dlx5 and Dlx6 expression in the embryonic striatum observed in the Dlx1/Dlx2 double knockout mouse (8). In addition, we have demonstrated similar transcriptional regulation of this enhancer by DLX2 but not DLX1 in the mouse retina, signifying a conservation of function of Dlx genes wherever these homeobox genes are expressed.
###end p 47
###begin p 48
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 75 78 75 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 229 232 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 238 241 238 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c3">3</xref>
###xml 246 247 246 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c5">5</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c11">11</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c12">12</xref>
###xml 295 298 295 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 304 307 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
The subtle phenotypes observed in the developing forebrain of the Dlx1 and Dlx2 single knockouts, as well as the overlapping expression domains and co-expression in subsets of embryonic striatum, support functional redundancy of Dlx1 and Dlx2 (3-5,11,12). However, there are differences between Dlx1 and Dlx2 expression during early development of the GE and retina. For example, in the GE, more DLX2 than DLX1 expressing cells are cycling at E12.5 (4). Onset of DLX1 and DLX2 expression in the retina occurs by E12.5 but more DLX2 than DLX1 expressing cells are in M-phase (4). These differences suggest that DLX1 and DLX2 may have different yet overlapping gene targets in developing forebrain and retina.
###end p 48
###begin p 49
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 227 230 227 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 371 379 371 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 431 439 431 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 590 598 590 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 865 868 865 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 881 884 881 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 887 890 887 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 896 899 896 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 901 904 901 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 917 918 917 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 919 920 919 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c5">5</xref>
###xml 921 923 921 923 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c12">12</xref>
###xml 911 915 <span type="species:ncbi:10090">mice</span>
DLX1 and DLX2 expression both significantly decrease by late gestation in the embryonic striatum. DLX1 and DLX2 bind to MI56 in E13.5 GE as demonstrated by ChIP assay. The activation of reporter gene expression by Dlx2 but not Dlx1 co-transfection with MI56 constructs suggests that DLX1 may require additional co-factors not present in the P19 embryonal carcinoma cells in vitro. However, luciferase and other reporter assays are in vitro 'non-chromatin' based methods. Hence, using ChIP, the investigator may detect binding without functional activation/repression of regulatory elements in vitro. The lack of demonstrated cooperation of DLX1 with DLX2 to activate the MI56 enhancer reporter gene suggests that DLX1 and DLX2 may have some non-overlapping functions during striatal neuronogenesis. These results support the functional differences observed between Dlx paralogs in Dlx1, Dlx2 and Dlx1/Dlx2 null mice (4,5,12).
###end p 49
###begin p 50
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c6">6</xref>
###xml 354 361 354 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 654 658 651 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 963 967 960 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 1044 1047 1041 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1056 1059 1053 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1390 1391 1387 1388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 1620 1623 1617 1620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1687 1690 1684 1687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1807 1810 1804 1807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
In the retina, DLX2 and DLX1 expression extends throughout embryogenesis, with DLX2 expressed in the adult. DLX1 expression resembles DLX2 to P0 but is significantly decreased postnatally (6). At P0, the binding of DLX2 but not DLX1 to the MI56 may reflect decreased DLX1 protein levels in the neonatal retina. Alternatively, binding of DLX1 to the MI56 in vivo may not be detected if the specific DLX1 antibody is not sufficiently sensitive to detect low levels of DLX1 protein or able to immunoprecipitate small quantities of DLX1 homeoprotein-MI56 enhancer DNA complexes. beta-gal antibody may be more sensitive than X-gal histochemistry in detecting lacZ expression since more cells are marked with the antibody at P0 and in the adult (data not shown). This could also reflect the possibility that the experimental conditions for tissue fixation and penetration of solutions may be less favorable for detection of the chromogenic substrate. The expression of lacZ in adult but minimally in neonatal retina is consistent with peak levels of Dlx5 and/or Dlx6 expression occurring after P0. Binding of DLX2 to the enhancer in retinal tissue at P0 may also reflect the relative sensitivity of the ChIP assay compared with routine histological detection, rather than false positive results. The ChIP protocol, which uses tissue from multiple embryonic or postnatal tissues to obtain 1-2 x 107 cells prior to processing and subsequent PCR amplification, is more likely to detect target sequences that are minimally expressed in developing tissues at a specific temporal or spatial coordinate. The retinal phenotype of the Dlx5/6 double knockout may be predicted to be more subtle than the Dlx1/2 null retina. Hence, unlike striatum, it may be helpful to perform ChIP at several time-points to obtain specific Dlx gene family targets in the developing and postnatal retina.
###end p 50
###begin p 51
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c23">23</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c27">27</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c29">29</xref>
###xml 386 394 386 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo.</italic>
###xml 526 536 526 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 598 605 598 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c28">28</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c30">30</xref>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c31">31</xref>
###xml 885 895 885 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 952 960 952 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 1028 1035 1028 1035 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 526 536 <span type="species:ncbi:7227">Drosophila</span>
###xml 885 895 <span type="species:ncbi:7227">Drosophila</span>
ChIP technology represented a major advance towards the identification of direct target genes of specific transcription factors, especially homeobox genes (23,27-29). The utilization of biochemical rather than genetic approaches, such as ChIP, provides several advantages. Identified target genes are directly downstream and derive from physiological homeodomain-DNA complexes obtained in vivo. Isolated gDNA fragments may be from regulatory elements of known or novel genes. ChIP may be applied to diverse species, including Drosophila and vertebrates. Cross-linking preserves naturally existing (in situ) protein-DNA interactions. Utilizing these methods, homeodomain targets have been isolated, including transcription factors, growth factors, adhesion molecules and secreted proteins (28,30,31). The search for homeobox targets in vertebrates has not yielded as many targets as in Drosophila. Although several candidates have been identified using in vitro and tissue culture methods, the significance of these interactions in vivo remains to be confirmed.
###end p 51
###begin p 52
###xml 10 15 10 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 18 20 18 20 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c24">24</xref>
###xml 125 131 125 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hox-C8</italic>
###xml 564 570 564 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hox-C8</italic>
###xml 927 932 927 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 935 937 935 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c32">32</xref>
###xml 137 142 <span type="species:ncbi:10090">mouse</span>
###xml 944 949 <span type="species:ncbi:9606">human</span>
Tomotsune et al. (24) used ChIP to identify a tumor suppressor gene and putative adhesion molecule as a downstream target of Hox-C8 from mouse spinal cord, suggesting that it is possible to isolate other direct vertebrate homeobox gene targets. However, the ChIP methodology used by this group may have presented several technical obstacles for subsequent isolation of other homeobox gene targets. For example, cross-linking was performed overnight using 4% PFA and the entire spinal cord was used as a tissue source rather than a region expressing high levels of Hox-C8. It is unclear whether the specific antibody they used had high affinity for this homeobox protein. Hence, many investigators have eschewed ChIP in favor of cDNA microarray or other techniques to find genes potentially regulated by their transcription factor of interest. Recently, ChIP has been successfully coupled with DNA microarray analysis. Weinmann et al. (32) used human CpG microarrays probed with immunoprecipitated chromatin to rapidly identify target promoters for the transcription factor E2F. Hence, combining ChIP and microarray technologies may improve both the efficiency and scale of standard ChIP approaches.
###end p 52
###begin p 53
###xml 202 209 202 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c4">4</xref>
###xml 559 562 559 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 568 571 568 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 635 638 635 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 656 663 656 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 711 714 711 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 750 758 750 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 763 766 763 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 778 783 778 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c25">25</xref>
###xml 824 827 824 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 882 885 882 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 940 943 940 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1053 1056 1053 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 894 899 <span type="species:ncbi:10090">mouse</span>
We have optimized the ChIP approach by reducing the concentration of the cross-linking reagent PFA and incubation time to preferentially obtain homeoprotein-genomic DNA complexes from embryonic tissues in situ. The polyclonal antisera to DLX1 and DLX2 have been subjected to a rigorous affinity purification process and are sensitive and highly specific (4). In addition, chromatin is derived from nuclear extracts derived from tissues where peak developmental expression of DLX1 and DLX2 occurs in distinct anatomical regions, enriching for the selection of Dlx1 and Dlx2 specific DNA target fragments. The identification of multiple Dlx target sequences in vivo will facilitate the elucidation of a consensus Dlx DNA binding site initially derived in vitro for Dlx3 by Feledy et al. (25). Finally, the expression of novel Dlx gene targets identified by ChIP may be altered in the Dlx1/2 null mouse, providing further understanding of how Dlx genes function throughout development. By combining genetic and molecular approaches, we will identify other Dlx-dependent target genes that are critical effectors of forebrain and retinal development. In addition, this optimized ChIP approach can be used to isolate direct targets of other transcription factors during vertebrate development.
###end p 53
###begin title 54
Figures and Tables
###end title 54
###begin p 55
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 561 562 561 562 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 564 567 564 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 621 624 621 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 641 644 641 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 664 667 664 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 781 788 781 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 861 864 861 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 913 916 913 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1000 1003 1000 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1009 1012 1009 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1123 1124 1123 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c6">6</xref>
###xml 1128 1129 1128 1129 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 1131 1134 1131 1134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1140 1143 1140 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1171 1174 1171 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1256 1259 1256 1259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1363 1370 1363 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 1471 1475 1471 1475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 1492 1495 1492 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1527 1531 1527 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 1575 1578 1575 1578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1717 1720 1717 1720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 1552 1557 <span type="species:ncbi:10090">mouse</span>
 (a) DLX2 expression in the developing forebrain and retina at E13.5. DLX2 is predominantly localized to the lateral (A) and medial (B) ganglionic eminences (LGE, MGE) as well as the retinal neuroepithelium (C) at this stage. There is a well-demarcated boundary of DLX2 expression at the GE-neocortical interface (small arrow). Migrating DLX2 immunoreactive cells, previously identified as GABAergic interneuron precursors, are visualized in the neocortex (NCx, long arrows). The boxed region outlines the regions of GE dissected for subsequent ChIP and EMSA. (b) Dlx isoform expression in the neonatal and adult retina. Dlx1 (panels A, D), Dlx2 (panels B, E) and Dlx5 (panels C, F) expression was determined at P0 (A-C) and in the adult (D-F) retina using digoxigenin-labeled RNA in situ hybridization. At P0, all three isoforms are expressed in the GCL, with Dlx2 expression predominating. In the adult retina, Dlx2 expression is evident in the GCL and inner nuclear layer (INL) (panel E), whereas Dlx1 and Dlx5 RNA expression are localized to the GCL more than the INL. DLX1 protein expression is not detected after P0 (6). (c) Dlx2 and Dlx5 are co-expressed with the Dlx5/6 intergenic enhancer in the retina. DLX2 protein (brown, nuclear staining) and Dlx5 RNA (purple, cytoplasmic staining) co-expression was established by combined immunohistochemistry and in situ hybridization in P0 (A) and adult (B) retinal tissue sections. Sections of adult retina stained for lacZ (blue) from the Dlx5/6 intergenic enhancer (MI56i) lacZ transgenic reporter mouse were probed with Dlx5 digoxigenin-labeled riboprobe (C, purple) and DLX2 antibody (D, brown), demonstrating co-localization of the MI56i enhancer element with Dlx5 and DLX2 in the GCL.
###end p 55
###begin p 56
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 63 70 63 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 489 490 477 478 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 570 577 558 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 794 795 782 783 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 848 855 836 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 868 871 856 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
 (a) Paraformaldehyde cross-links DLX1 and DLX2 to nuclear DNA in situ. DLX1 and DLX2 are immunoenriched in E13.5 GE. 1% PFA improves cross-linking of DLX proteins compared with 4% PFA. Protein samples were obtained from embryonic liver (negative control), whole E12.5 embryo (positive control), E13.5 GE and E13.5 GE cross-linked with 4% or 1% PFA for 2 h. Blots shown in A, B and C were immunostained with alphaDLX1, alphaDLX2 and anti-histone deacetylase-1 (alphaHDAC1), respectively. (b) Duration of exposure to PFA affects the yield of homeoprotein-DNA cross-links in situ. Dissected GE at E13.5 were cross-linked with 1% PFA from 30 min to overnight. Peak levels of both DLX1 and DLX2 were detected at 90 min. Overnight exposure to PFA significantly abrogates detection of DLX proteins. (c) Cisplatin cross-links DLX1 and DLX2 to nuclear DNA in situ. Cisplatin (cis-DDP) was also used to cross-link DLX homeoproteins from E13.5 GE. Blots shown in Panels A, B and C were immunostained with alphaDLX1, alphaDLX2 and anti-histone deacetylase-1 (alphaHDAC1), respectively.
###end p 56
###begin p 57
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 34 37 34 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 43 46 43 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 48 51 48 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 84 87 84 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hox</italic>
###xml 181 184 181 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 296 299 296 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 301 304 301 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 376 378 376 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 453 456 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 477 480 477 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 482 485 482 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c33">33</xref>
###xml 518 519 518 519 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 598 601 598 601 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 603 606 603 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 751 756 751 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 759 761 759 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkh233c13">13</xref>
###xml 1007 1008 1007 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f5">5</xref>
###xml 1014 1015 1014 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkh233f6">6</xref>
###xml 77 82 <span type="species:ncbi:10090">mouse</span>
 (a) Genomic organization of Dlx1/Dlx2 and Dlx5/Dlx6 bigenic clusters in the mouse. Hox genes are sequentially oriented in a 3'-5' direction from anterior to posterior, whereas the Dlx gene family is organized in three bigenic clusters with the genes facing one another as 5'-3' 3'-5' pairs. The Dlx5/Dlx6 intergenic region MI56 contains two enhancer regions, I56i and I56ii (13). The 60 amino acid homeodomain (shaded boxes) is highly conserved across Dlx family members. The Dlx3/Dlx7 cluster is not included (33). (b) Sequence and organization of candidate homeodomain DNA binding motifs in the Dlx5/Dlx6 intergenic enhancer. The MI56 sequence (GenBank, AY168010), is shown for two enhancer elements, I56i and i56ii, initially described by Zerucha et al. (13). Putative TAAT/ATTA homeodomain DNA binding motifs are highlighted in bold italics. The two underlined I56i sequences represent the 6th and 9th motifs critical for DLX1 and/or DLX2 binding and transcriptional activation demonstrated in Figures 5b and 6, respectively.
###end p 57
###begin p 58
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 45 48 45 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 94 101 94 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 354 357 354 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 493 500 493 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 554 555 554 555 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 602 605 602 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 648 655 648 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 824 831 824 831 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 834 835 834 835 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 884 887 884 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 934 941 934 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
###xml 1117 1124 1117 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
 (a) Chromatin IP: DLX1 and DLX2 bind to the Dlx5/6 intergenic enhancer in embryonic striatum in situ. E13.5 GE was cross-linked with 1% PFA and immunoprecipitated with specific DLX1 or DLX2 antibodies. After isolation of genomic DNA fragments bound to DLX1 or DLX2 homeoproteins, PCR using oligonucleotide primers to two regions (I56i and I56ii) of the Dlx5/6 intergenic region was performed. Total genomic DNA was used as a positive control. Both DLX1 and DLX2 bind to I56i but not to I56ii in situ. PCR products were subcloned and sequence-verified. (b) Chromatin IP: DLX2 but not DLX1 binds to the Dlx5/6 intergenic enhancer in neonatal retina in situ. ChIP was performed using P0 retina and specific DLX1 or DLX2 antibodies. In the P0 retina, only DLX2 binds to I56i; neither DLX1 nor DLX2 binds to I56ii in the retina in situ. (c) Chromatin IP: DLX1 and DLX2 do not bind to the Dlx5/6 intergenic enhancer in embryonic hindbrain in situ. E13.5 hindbrain was selected as a negative tissue control for ChIP with specific DLX1 or DLX2 antibodies. In embryonic hindbrain, neither DLX1 nor DLX2 bind to I56i or I56ii in situ.
###end p 58
###begin p 59
###xml 2 3 2 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 100 103 100 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 105 108 105 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 130 138 130 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 762 763 762 763 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 877 880 877 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 882 885 882 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 907 914 907 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ</italic>
 (a) Electrophoretic mobility shift assays (EMSA) demonstrate recombinant DLX1 and DLX2 bind to the Dlx5/Dlx6 intergenic enhancer in vitro. EMSA was performed using recombinant DLX1 or DLX2 proteins and a radiolabeled I56i oligonucleotide probe, with cold competition (lanes 3 and 7) and specific DLX antibody 'supershift' assays (lanes 4 and 8). Lane 1: labeled I56i alone. Lanes 2-5: labeled I56i probes were incubated with rDLX1 (2), rDLX1 and unlabeled I56i (3), rDLX1 and anti-DLX1 (4), and rDLX1 and an irrelevant antibody (5). Lanes 6-9: I56i probes were incubated with rDLX2 (6), rDLX2 and unlabeled I56i (7), rDLX2 and anti-DLX2 (8), and rDLX2 and irrelevant antibody (9) (r: recombinant; 1: DLX1/anti-DLX1; 2: DLX2/anti-DLX2; I: irrelevant antibody). (b) EMSA of embryonic striatum demonstrates DLX1 and DLX2 binding to specific homeodomain binding motifs within the Dlx5/Dlx6 intergenic enhancer in situ. EMSA was performed using E13.5 GE tissue nuclear extracts and oligonucleotides for four TAAT/ATTA DNA binding motifs contained within I56i. Only the sixth and ninth motifs bound to E13.5 GE. (A) EMSA for homeodomain binding motif 9 (8853-8860 bp, lanes 1-6). (B) EMSA for motif 6 (8797-8804 bp, lanes 7-12). Cold competition assays are shown in lanes 3 and 9. Supershift assays with specific DLX antibodies are seen in lanes 4 and 10 (alphaDLX1) and lanes 5 and 11 (alphaDLX2).
###end p 59
###begin p 60
###xml 21 24 21 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 105 113 105 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
 DLX2 binding to the Dlx5/Dlx6 intergenic enhancer activates transcription of a luciferase reporter gene in vitro. In P19 embryonic carcinoma cells, a luciferase gene reporter construct containing I56i, or I56i with mutations of the 6th or 9th homeodomain DNA binding motifs, was co-transfected with expression constructs for DLX1 or DLX2. DLX2, but not DLX1, co-transfection activated reporter gene expression. Site-directed mutagenesis of the sixth TAAT motif significantly reduced reporter gene activity for DLX2 co-transfection.
###end p 60
###begin title 61
ACKNOWLEDGEMENTS
###end title 61
###begin p 62
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Dlx</italic>
###xml 153 157 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lacZ</italic>
###xml 178 183 <span type="species:ncbi:10090">mouse</span>
###xml 245 250 <span type="species:ncbi:39350">Basil</span>
We thank Jeff Wigle and Spencer Gibson for critical review of the manuscript. We are grateful to Marc Ekker for providing the Dlx5/6 intergenic enhancer lacZ reporter transgenic mouse eye tissues used in this study. This work was supported by a Basil O'Connor Starter Scholar Award from the March of Dimes Birth Defects Foundation 5-FY00-615 (to D.D.E.), an operating grant from the CancerCare Manitoba Foundation (to J.R.D. and D.D.E) and an Establishment Grant from the Manitoba Health Research Council (to D.D.E.). T.N.L. was supported by a Canadian Institutes of Health Research Training Program Grant.
###end p 62
###begin title 63
REFERENCES
###end title 63

